Parkinson's Blog

Bayer’s bemdaneprocel will now progress to pivotal Phase III Parkinson’s trials after demonstrating trends towards a disease-modifying impact.

Parkinson’s Disease Treatment Market size is expected to reach US$ 11.28 Billion by 2034, from US$ 6.42 Billion in 2024, at a CAGR of 5.8%.

A new phase 2 trial explores probiotics’ potential to alleviate depression and mood disorders in patients with Parkinson disease, linking gut health to mental well-being.

Key Takeaways

A groundbreaking imaging technique has, for the first time, made the invisible visible. For the first time, scientists have managed to directly observe and measure the protein clusters thought to spark the onset of Parkinson’s disease, representing a major leap forward in understanding this rapidly

Gain Therapeutics reports positive early data from Parkinson’s trial

Scientists uncover how PP2A-B55α maintains brain energy balance and offers hope for Parkinson’s and mitochondrial diseases.

Sheelagh Wurr set up Salisbury Shakers after being diagnosed with an essential tremor in her 40s

In a groundbreaking development that could revolutionize the approach to neurodegenerative and mitochondrial diseases, researchers have identified a pivotal cellular mechanism governing energy balance and mitochondrial quality control. This discovery centers on phosphatase B55,

Currently, 15 other states use similar systems to help pinpoint risks.